Phaseline

Targets › IFNGR1

IFNGR1 (Interferon gamma receptor 1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 2; Infectious disease, Oncology; next expected readout Nov 2026.

Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Associates with transmembrane accessory factor IFNGR2 to form a functional receptor. (UniProt, P15260)

Open in Phaseline: the race on IFNGR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Manchester University NHS Foundation TrustInterferon Gamma-1B
Interferon gamma receptor agonist
IFNGR2, IFNGR1Phase 2Chronic Pulmonary AspergillosisNov 2026
University Hospital, Basel, SwitzerlandInterferon Gamma-1B
Interferon gamma receptor agonist
IFNGR2, IFNGR1Phase 2Adenovirus InfectionDec 2026
Sawa Ito, MDInterferon gamma-1b
Interferon gamma receptor agonist
IFNGR2, IFNGR1Phase 2Acute Myeloid LeukemiaOct 2029

Conditions

Acute Myeloid Leukemia (1) Chronic Pulmonary Aspergillosis (1) Adenovirus Infection (1)

Modalities

protein or peptide (1), other (1)

Companies

Sawa Ito, MD (1) Manchester University NHS Foundation Trust (1) University Hospital, Basel, Switzerland (1)

Related targets

IFNGR2 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.